Applying real-world data from expanded-access (“compassionate use”) patients to drug development

Our drug development process has produced many life-saving medications, but patients experiencing rare diseases and similar conditions often are left with limited options for treatment. For an approved treatment to be developed, research on a new candidate or existing drug must validate safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasser, June S., Greenblatt, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Special Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495823/
https://www.ncbi.nlm.nih.gov/pubmed/37706004
http://dx.doi.org/10.1017/cts.2023.606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495823/
https://www.ncbi.nlm.nih.gov/pubmed/37706004
http://dx.doi.org/10.1017/cts.2023.606

Ejemplares similares